Randomized, double-blind comparison of acute beta1-blockade with 50 mg metoprolol tartrate vs 25 mg carvedilol in normal subjects.
暂无分享,去创建一个
David S. Hirsh | C. Tseng | K. Ramanathan | R. Jeger | F. Haas | U. Jorde | C. Barker | Alhakam Hudaihed | Rana Billeh | B. Jørgensen | Colin M. Barker
[1] C. Lavie,et al. Peak exercise oxygen pulse and prognosis in chronic heart failure. , 2004, The American journal of cardiology.
[2] P. Poole‐Wilson,et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.
[3] B. Fagerberg,et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.
[4] F. Fruhwald,et al. Differing beta‐blocking effects of carvedilol and metoprolol , 2001, European journal of heart failure.
[5] D. DeMets,et al. Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.
[6] M. Domanski,et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.
[7] D. Jorkasky,et al. Steady‐State Pharmacokinetics of Carvedilol and Its Enantiomers in Patients with Congestive Heart Failure , 2000, Journal of clinical pharmacology.
[8] H. Whittle,et al. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa , 1999, The Lancet.
[9] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[10] K. Adams,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.
[11] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[12] K. Breithaupt-Grögler,et al. Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. , 1994, British journal of clinical pharmacology.
[13] Hung‐Yuan Cheng,et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.
[14] J. Wilmore,et al. Effects of beta-blockade on exercise capacity of trained and untrained men: a hemodynamic comparison. , 1986, Journal of applied physiology.
[15] J. Wilmore,et al. Effects of cardioselective and nonselective beta-adrenergic blockade on the performance of highly trained runners. , 1985, The American journal of cardiology.
[16] W. Kraus,et al. Effects of beta 1-selective and nonselective beta-adrenoceptor blockade during exercise conditioning in healthy adults. , 1984, The American journal of cardiology.
[17] B. Whipp,et al. Effects of beta-adrenergic blockade on ventilation and gas exchange during exercise in humans. , 1983, Journal of applied physiology: respiratory, environmental and exercise physiology.
[18] D. Hosmer,et al. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. , 1973, American heart journal.
[19] P. Lundborg,et al. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: A comparison with atenolol , 2004, European Journal of Clinical Pharmacology.
[20] P. Rønnevik,et al. Functional capacity in healthy volunteers before and following β-blockade with controlled-release metoprolol , 2004, European Journal of Clinical Pharmacology.